Buscar
Mostrando ítems 1-5 de 5
Artículo
Consenso de expertos españoles sobre el uso de la safinamida en la enfermedad de Parkinson
(Elsevier, 2018-04-18)
La safinamida es un nuevo fármaco para el tratamiento de pacientes con enfermedad de Parkinson (EP) con fluctuaciones como tratamiento complementario a levodopa. Dado que por el momento aún no existen estudios de fase IV ...
Artículo
Predictors of clinically significant quality of life impairment in Parkinson’s disease
(Springer, 2021)
Quality of life (QOL) plays an important role in independent living in Parkinson’s disease (PD) patients, being crucial to know what factors impact QoL throughout the course of the disease. Here we identified predictors ...
Artículo
Early downregulation of hsa-miR-144-3p in serum from drug-naïve Parkinson’s disease patients
(Nature Publishing Group, 2022)
Advanced age represents one of the major risk factors for Parkinson’s Disease. Recent biomedical studies posit a role for microRNAs, also known to be remodelled during ageing. However, the relationship between microRNA ...
Artículo
Non‑motor symptom burden in patients with parkinson’s disease with impulse control disorders and compulsive behaviours: results from the coppADiS cohort
(Springer Nature, 2020)
The study was aimed at analysing the frequency of impulse control disorders (ICDs) and compulsive behaviours (CBs) in patients with Parkinson’s disease (PD) and in control subjects (CS) as well as the relationship between ...
Artículo
Consenso de expertos españoles sobre el uso de la safinamida en la enfermedad de Parkinson
(Science Direct, 2021)
La safinamida es un nuevo fármaco para el tratamiento de pacientes con enfermedad de Parkinson (EP) con fluctuaciones como tratamiento complementario a levodopa. Dado que por el momento aún no existen estudios de fase IV ...